Stay updated on IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe record describes a completed Phase 2 metastatic melanoma study of tilsotolimod with ipilimumab, with details on eligibility, study sites, treatment, and outcome measures. It also includes study documents and record dates.SummaryDifference57%

- Check16 days agoChange DetectedThe displayed site revision changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA notice appears at the top of the page announcing NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.” The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check29 days agoChange DetectedThe site's footer revision identifier changed from v3.7.1 to v3.7.2, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer now identifies the release as v3.7.1 instead of v3.7.0. The page continues to show a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check57 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden error, preventing viewing the study details. This reflects a site access issue rather than a substantive update to the content.SummaryDifference19%

Stay in the know with updates to IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.